The latest update is out from Centessa Pharmaceuticals (CNTA).
Centessa Pharmaceuticals has announced FDA clearance for the Phase 1 trial of their new drug, ORX750, aimed at treating narcolepsy. The upcoming trial will assess the drug’s safety and dosage effects in healthy adults using sleep latency and sleepiness scales, with expectations to start dosing soon and to have proof-of-concept data available in the latter half of 2024. This marks a significant step for the company in developing treatments for sleep-related disorders.
Learn more about CNTA stock on TipRanks’ Stock Analysis page.
